Business Context and Reporting Period
This Form 8-K is filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) on February 29, 2024. The filing serves to announce the results of operations for the fourth quarter and full year ended December 31, 2023. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The filing text does not provide a clear value regarding specific material changes versus the prior comparable period. It only indicates that such results were announced in a separate press release.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc., not Dogwood Therapeutics, Inc.
- Locate and review Exhibit 99.1 (Press Release dated February 29, 2024) to obtain actual Q4 and full-year 2023 financial figures.
- Confirm the company's status as an emerging growth company (indicated by a checkmark in the filing).
- Note that the information in this 8-K is "furnished" and not deemed "filed" for purposes of Section 18 of the Exchange Act.